Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

7.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
7.2K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.2K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

6
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
6
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

2.7K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.7K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

5.9K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-term pre-meal whey protein microgel supplementation reduces postprandial glycemia and appetite in adults with overweight: An open-label randomised controlled trial.

Obesity pillars·2025
Same author

Glucose-dependent insulinotropic polypeptide (GIP).

Molecular metabolism·2025
Same author

A Randomized, Placebo-Controlled, Single-Center, Crossover Study to Evaluate the Effects of Pre-Meal Whey Protein Microgel on Post-Prandial Glucometabolic and Amino Acid Response in People with Type 2 Diabetes and Overweight or Obesity.

Metabolites·2025
Same author

Total adiponectin in indigenous Melanesians on Kitava.

American journal of human biology : the official journal of the Human Biology Council·2024
Same author

The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice.

Peptides·2023
Same author

Paradigm Shift in the Management of Metabolic Diseases-Next-Generation Incretin Therapy.

Endocrinology·2023
Same journal

Ablation of microglial estrogen receptor alpha predisposes male mice to diet-induced obesity.

Metabolism: clinical and experimental·2026
Same journal

Pathophysiology-based subtypes of individuals at high risk of type 2 diabetes: multi-omics profiles and lifestyle differences across subtypes.

Metabolism: clinical and experimental·2026
Same journal

A thermosensitive TET-Parkin epigenetic axis couples mitochondrial quality control to adaptive thermogenesis in adipose tissue.

Metabolism: clinical and experimental·2026
Same journal

Raffinose targets the NQO1/NF-κB axis to attenuate DON-driven microglial activation and neuroinflammation via metabolic reprogramming.

Metabolism: clinical and experimental·2026
Same journal

Endothelial NPR-C promotes insulin resistance via Caveolin-1-mediated insulin transcytosis.

Metabolism: clinical and experimental·2026
Same journal

Macrophage-enriched GPR91 aggravates acute liver injury by inhibiting efferocytosis via the AC/cAMP/PPARγ pathway.

Metabolism: clinical and experimental·2026
See all related articles

Related Experiment Video

Updated: Apr 22, 2026

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets
09:31

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets

Published on: June 25, 2012

13.4K

Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function.

Bilal Omar1, Maria Sörhede-Winzell1, Bo Ahrén1

  • 1Lund University, Department of Clinical Sciences, Lund, Sweden.

Metabolism: Clinical and Experimental
|October 11, 2014
PubMed
Summary
This summary is machine-generated.

Increased glucagon receptor expression in beta cells alters insulin secretion, impairing responses to GLP-1 and arginine but exaggerating glucose-stimulated insulin secretion. This suggests complex effects in type 2 diabetes.

Keywords:
Beta cell functionGLP-1GlucagonInsulin

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

97.5K
A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.2K

Related Experiment Videos

Last Updated: Apr 22, 2026

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets
09:31

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets

Published on: June 25, 2012

13.4K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

97.5K
A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.2K

Area of Science:

  • Endocrinology
  • Diabetes Research
  • Islet Biology

Background:

  • Glucagon receptor expression is elevated in pancreatic islets of individuals with type 2 diabetes.
  • The functional impact of this increased expression on beta-cell function remains unclear.

Purpose of the Study:

  • To investigate how elevated beta-cell glucagon receptor expression affects various aspects of beta-cell function.
  • To determine the role of glucagon receptor signaling in regulating insulin secretion.

Main Methods:

  • Utilized genetically modified mice with beta-cell specific overexpression of the glucagon receptor (RIP-Gcgr).
  • Administered intravenous glucose tolerance tests, glucagon, GLP-1, arginine, and carbachol challenges.
  • Evaluated insulin secretory responses under different stimulation conditions.

Main Results:

  • Beta-cell specific glucagon receptor overexpression led to dissociated effects on insulin secretion.
  • Potentiating effects of GLP-1 and arginine on glucose-stimulated insulin secretion were abolished.
  • Insulin response to carbachol was largely unaffected, while glucose-stimulated insulin secretion was exaggerated.

Conclusions:

  • Overexpression of glucagon receptors in beta cells, observed in hyperglycemia, has complex and varied effects on insulin secretion.
  • These findings suggest a potential role in regulating beta-cell function during fasting, post-meal, and in response to autonomic activation in diabetes.